General Information
G34R/V mutated gliomas are considered a rare disease and are often diagnosed in the young adult/adolescent population. Despite improvements in the diagnostic landscape of these aggressive high grade gliomas, the therapeutic advancements have lagged, leaving clinicians to struggle with optimal treatment options.
During this conference, we will review published and ongoing research centered on G34R/V mutated glioma discoveries to date and discuss via small groups and larger forums on how best to advance research as well as treat these complex patients.
This comprehensive day-long conference is designed for neurooncologists, neurooncology researchers, tumor biologists, oncologists, neurologists, neurosurgeons, neuropathologists, advanced practice nurses, nurses, physician assistants, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with malignant brain tumors.
Meeting Contacts
- Jackson, Sadhana sadhana.jackson@nih.gov
- Hill, Melissa melissa.hill@roseliassociates.com
- Castro, Maria mariacas@med.umich.edu
Sponsored By
- National Institutes of Neurological Disorders and Stroke (NINDS)
- National Cancer Institute (NCI)
- National Center for Advanced Sciences and Technology (NCATS)
- Foundation for Advanced Education in the Sciences (FAES)
Sessions/Agenda
Friday, May 31, 2024
07:30 AM-05:00 PM(EST)
Rockledge II
6701 Rockledge Drive,
Bethesda, MD - 20817
Logistics
Visitor Information
Symposium Location
This meeting will take place at Rockledge II, 6701 Rocklege Drive, Bethesda, MD 20817. While very close, none of the sessions will take place on the NIH main Bethesda campus. Individuals with disabilities who need reasonable accommodation to participate in this event should contact Melissa Hill at melissa.hill@roseliassociates.com.
Meals
Morning and afternoon meals will all be provided on site. Warm breakfast with coffee/tea will be served (courtesy of NIH FAES). A delicious warm lunch with beverage selections will be provided (courtesy of Chimerix).
Lodging
Shuttle service will provide transportation from Embassy Suites by Hilton Bethesda, starting at 7:15am and provide return trips to the hotel at approximately 5:15pm.
Driving Directions
From I-495 (Capital Beltway) in Northern Virginia:
Take I-495 (Capital Beltway) northbound (Inner Loop).
Stay to the left and enter I-270 North at the I-270 spur.
Take Exit 1 to Democracy Boulevard.
At the third traffic light, turn left onto Fernwood Drive.
At the third traffic light, turn right onto Rockledge Drive.
Follow Rockledge Drive about 1/2 mile.
Rockledge I & II are located on your left.
From I-495 (Capital Beltway) in Maryland:
Take I-495 (Capital Beltway) westbound (Outer Loop).
Stay to the right to enter I-270 North at the I-270 spur.
Take Exit 1B and turn left at the traffic light at the top of the ramp onto Rockledge Drive.
At the first light, yield to the right to stay on Rockledge Drive.
Rockledge I & II are located on your right.
Parking
At 6701 and 6705 Rockledge Drive parking lots, the building owner has marked designated parking spaces that may include, but are not limited to, TENANT PARKING, VISITOR PARKING, RESERVED PARKING, HANDICAP PARKING, NO PARKING, etc. Any space not otherwise marked is designated for TENANT ONLY PARKING.
Tenant Parking
Tenants must have a valid NIH parking permit issued by ORS displayed in their vehicle at all times in order to park in the parking lots. Parking hangers must be displayed without obstructions. Parking hangers must be hung from the rearview mirror and dash board permits must be placed on the drivers' side dashboard. Vehicles with no permit or failure to display the parking permit properly, may result in the vehicle being towed from the premises.
Visitor/Guest Parking
Visitor/Guest: A person who is NOT a tenant in the building as a permanent duty station.
- Visitor/Guest parking is only allowed in spaces designated for "VISITOR/GUEST PARKING."
- Tenants are not eligible for Visitor/Guest Parking.
- All Visitor/Guest must obtain a valid temporary parking plaque from the guard's desk located in the lobbies of either 6701 and 6705 Rockledge Drive. This plaque must be displayed on the driver's dashboard at all times while vehicle is parked on the premises.
Additional Parking
Additional parking can be found at nearby public parking garages.
- 6720 Rockledge Drive, Bethesda, MD 20817
- 6700 Rockledge Drive, Bethesda, MD 20817
- 6555 Rock Spring Drive, Bethesda, MD 20817
Building Security
At the building entrances where guards are posted:
- Employees must show a DHHS-issued photo ID (for example, your NIH-issued ID badge).
- Visitors may be required to log in, wear a visitors pass and have an employee escort them through the building.
- Visitors may be required to pass through a metal detector and have bags, backpacks or purses inspected or x-rayed as they enter buildings.
- Security staff will be looking for and confiscating any suspicious or potentially dangerous materials. U.S. Code prohibits bringing any dangerous weapons onto Federal property, including anything with a blade longer than 2 1/2 inches. Meeting participants may want to leave extra bags or personal materials at their hotel to minimize the time needed for inspection.
After-hours building access will require the use of an employee ID on electronic access card readers at building entrances and certain internal areas.
7:30am - 8:00am Registration and Breakfast
8:00am - 8:05am Welcome and Opening Remarks
o Sadhana Jackson, MD, Tenure-track Investigator, Head of Developmental Therapeutics, NCI, Pediatric Oncology Branch and NINDS, Surgical Neurology Branch, NIH
o Maria Castro, PhD, Professor of Neurosurgery and Cell and Developmental Biology, University of Michigan
8:05am - 9:05am Overview of G34R/V Glioma
o Epidemiology of Gliomas in AYA population
Quinn Ostrom, PhD, Assistant Professor, Neurosurgery, Population Health Sciences, Duke University, School of Medicine
o Neuropathology: An Update for the Clinician
Patrick J Cimino, MD, Staff Clinician
Surgical Neurology Branch, NINDS, NIH
o Neuroimaging features of G34R/V mutated gliomas
Sohil Patel, MD, Associate Professor, Radiology and Medical Imaging Department, University of Virginia Health
o Panel Question and Answers
Moderated by Sadhana Jackson
9:05am - 10:40am
Surgical Management and Genomics of G34R/V Diffuse Gliomas
o Historical lens of Diffuse Gliomas
Suzanne Baker, MD, Endowed Chair in Brain Tumor Resarch, Developmental Neurobiology, St. Jude Childern's Research Hospital
o Surgical Challenges and Precision Therapy for Cortical Gliomas
Chetan Bettagowda, MD, PhD, Professor, Director, Reza Khatib Brain Tumor Center, Johns Hopkins Hospital
o Methylation of Glioma
Houtan Noushmehr, PhD, Associate Professor of (epi)Genomics and Bioinformatics, Henry Ford Health System
o Neuro-glial cellular architecture driven by G34R mutation
Mario Suva, MD, PhD, Associate Professor of Pathology, Harvard Medical School and Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center
o Computational Genomics
Claudia Kleinman, Associate Member, Assistant Professor, McGill Centre for Translational Research in Cancer, Lady Davis Institute for Medical Research, McGill University
o Panel Question and Answers
Moderated by Suzanne Baker
10:40am - 10:55am Break and Poster Exhibition
10:55am - 12:15pm Translational Research
o Characterization of the Immune Microenvironment
Maria Castro, PhD, Professor of Neurosurgery and Cell and Developmental Biology, University of Michigan
o Implementation of Immune mediated Gene therapeutics in H3.3G34R mutated high grade gliomas
Pedro Lowenstein, Professor of Neurosurgery, Professor, Cell and Developmental Biology, University of Michigan
o Base excision repair: A promising therapeutic target in H3G34 mutant diffuse hemispheric glioma
Laura Canty, PhD, Research Project Coordinator, University of Toronto, The Hospital for Sick Kids
o Gabaergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant Gustavo A.V. Cruzeiro, Postdoctoral Fellow, Dana-Farber Cancer Institute
o Panel Question and Answers
Moderated by Sadhana Jackson
12:00am - 1:00pm Lunch and Poster Session
1:00pm ¿ 2:05pm Small Group Discussions -clinicians/scientists mixed in each group
o Identifying and Addressing Gaps in Diagnosis, Clinical Care and Research (written answers)
Leads: Nellan, Castro, Becher
o Sharing (presentation of each small group with discussion)
2:05pm - 3:40pm
Management of G34R/V Gliomas: What Trials and Research are on the Horizon?
o Overview of NCI/NINDS Sponsored Clinical Trials
Sadhana Jackson, MD, Tenure-track Investigator, Head of Developmental Therapeutics, NCI, Pediatric Oncology Branch and NINDS, Surgical Neurology Branch, NIH
o G34R/V therapeutic targeted clinical trial
Tom Davidson, MD, Associate Professor of Pediatrics, Children's Hospital of Los Angeles, Keck School of Medicine of USC
o Tumor Genomics: What Every Clinician Needs to Know
Adam Resnick, PhD, Co-Director of Data Driven Discovery in Biomedicine and Scientific Chair for Children¿s Brain Tumor Network and Pacific Pediatric Neuro-Oncology Consortium
o Chemokines in myeloid-tumor cell crosstalk in pediatric high-grade gliomas
Delores Hambardzumyan, PhD, MBA, Professor of Oncological Sciences and Neurosurgery, Mount Sinai. o G34R/V therapy: Learning from other pHGG trials and subtypes
Adam Green, Associate Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation, University of Colorado Anschutz School of Medicine
o Biotherapeutic delivery for brain cancer: Landscape and new approaches to cross the blood-brain barrier
Robert Thorne, PhD, Denali Fellow, Denali Therapeutics
o What can be learned with high throughput drug screening for H3.3 K27? Kelli Wilson, PhD, Acting Director of Compound Management, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH
o Panel Question and Answers
Moderated by Maria Castro
3:40pm -4:00pm Break | Poster Exhibition-Meet the Experts
4:00pm - 4:50pm Tumor Board Cases
o G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Brett Theeler, MD
Panel
o Pathologist: Jason Gregory, MD
o Radiation Oncologist: Peter Mathen
o Neurosurgeon: Karin Muraszko
o Radiologist: Nadia Biassou, MD
o G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Oren Becher, MD
Panel
o Pathologist: Patrick J Cimino
o Radiation Oncologist: Peter Mathen
o Neurosurgeon: Karin Muraszko
o Radiologist: Nadia Biassou, MD
o G34R Tumor Board Case: Management recurrent disease | | Case Presenter, Sheila McThenia, MD
Panel
o Pathologist: Dr. Patrick J Cimino
o Radiation Oncologist: Peter Mathen
o Neurosurgeon: Karin Muraszko
o Radiologist: Nadia Biassou
4:50pm - 5:00pm
Closing Remarks
Sadhana Jackson, MD and Maria Castro, PhD
(U.S. Department of Health and Human Services)